Two technologies that could reduce the severity of the symptoms of chronic tic disorders and Tourette syndrome have been recommended for use in draft guidance from NICE. It is the first time a NICE ...

According to the study, technologies that received scientific advice took a median of 312 days to progress from marketing authorisation to NICE guidance publication. In contrast, those without such ...

Are you facing challenges in quickly bringing new healthtech products to market? The NHS is a large and complex system and ...

There is a simple discount patient access scheme for elafibranor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

AI encompasses the use of digital technology to create systems capable of performing tasks commonly thought to require human intelligence. This includes machine learning approaches. Given the rapid ...

There is a simple discount patient access scheme for teclistamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The evaluation committee considered evidence submitted by Ipsen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Elafibranor (Iqirvo, Ipsen) is indicated for 'the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as ...